The historical rank and industry rank for Lasa Supergenerics's Net Margin % or its related term are showing as below:
NSE:LASA'
s Net Margin % Range Over the Past 10 Years
Min: -135.6 Med: -5.49 Max: 11.25
Current: -135.6
NSE:LASA's Net Margin % is ranked worse than 92.47% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs NSE:LASA: -135.60
Lasa Supergenerics (NSE:LASA) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Lasa Supergenerics Net Margin % Related Terms
Lasa Supergenerics Net Margin % Historical Data
* Premium members only.
The historical data trend for Lasa Supergenerics's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lasa Supergenerics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lasa Supergenerics Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lasa Supergenerics's Net Margin % distribution charts can be found below:
* The bar in red indicates where Lasa Supergenerics's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lasa Supergenerics (NSE:LASA) has a Net Margin % of 3,166.84% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Lasa Supergenerics and its competitors. According to the industry distribution chart, Lasa Supergenerics ranks #884 out of 956 companies in the Drug Manufacturers industry, placing it in the top 92.5%.
Is Lasa Supergenerics' Net Margin % too high?
Lasa Supergenerics' current Net Margin % is 3,166.84%. The Drug Manufacturers industry median Net Margin % is 5.56. Lasa Supergenerics' value of 3,166.84% is 56857.6% above this industry median. Based on the distribution chart, Lasa Supergenerics ranks #884 out of 956 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Lasa Supergenerics has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lasa Supergenerics' Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Lasa Supergenerics ranks #884 out of 956 companies for Net Margin %. This places Lasa Supergenerics in the lower half of its industry. The industry median Net Margin % is 5.56. Lasa Supergenerics' value of 3,166.84% is 56857.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lasa Supergenerics's current Net Margin % of 3,166.84% is 56857.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Lasa Supergenerics and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lasa Supergenerics's current Net Margin % is 3,166.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lasa Supergenerics stock overvalued right now?
Based on GuruFocus' analysis, Lasa Supergenerics (NSE:LASA) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹4.36, compared to a current price of ₹7.60 — trading 74.3% above its estimated fair value. The current Net Margin % is 3,166.84% and 56857.6% above the Drug Manufacturers industry median of 5.56. Lasa Supergenerics' overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Lasa Supergenerics (NSE:LASA), the current Net Margin % is 3,166.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lasa Supergenerics (NSE:LASA) Overvalued in 2026?
Based on GuruFocus' analysis, Lasa Supergenerics stock appears to be overvalued.
The current stock price of ₹7.60 is trading 74.3% above its estimated GF Value™ of ₹4.36.
GuruFocus considers Lasa Supergenerics to be Significantly Overvalued.
Key valuation signals for NSE:LASA:
Net Margin %: 3,166.84%
GF Value™: ₹4.36 vs. price of ₹7.60 (74.3% above fair value)
Industry Position: 56857.6% above the Drug Manufacturers median (#884 of 956)
No single metric tells the full story. See the NSE:LASA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lasa Supergenerics Ltd is engaged in the research, manufacturing, trading, producing, processing, preparing, and treating chemicals, API, pharmaceuticals, drugs, and related products. The company specializes in catalyst chemistry and manufactures anthelmintic and veterinary API products. Its product range includes API products, other API products, animal feed ingredients, and reagents for therapeutic use.
46GF Score
Get the complete analysis for NSE:LASA
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:LASA has been successfully added to your 
